Kansanterveyslaitos KTL

Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study

Karvonen M; Cepaitis Z; Tuomilehto J
BMJ (1999)

Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV 16 vaccination

Kibur M; Geijerstamm V af; Pukkala E; Koskela P; Luostarinen T; Paavonen J; Schiller J; Wang Z; Dillner J; Lehtinen M
Sexually Transmitted Infections : Feb (2000)

Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise

Torvinen S; Nieminen P; Lehtinen M; Paavonen J; Demarteau N; Hahl J
Journal of Medical Economics : 2 (2010)

Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing

Lehtinen M; Apter D; Dubin G; Kosunen E; Isaksson R; Korpivaara EL; Kyhä-Österlund L; Lunnas T; Luostarinen T; Niemi L; Palmroth J; Petäjä T; Rekonen S; Salmivesi S; Siitari-Mattila M; Svartsjö S; Tuomivaara L; Vilkki M; Pukkala E; Paavonen J
INT J STD AIDS : 8 (2006)

Low mumps antibody levels induced by mumps-measles-rubella vaccinations in type 1 diabetic children

Hiltunen M; Hyöty H; Leinikki P; Åkerblom HK; Tuomilehto J; Vesikari T; Childhood Diabetes in Finland (DiMe) Study Group
Diabet Med (1994)

No evidence of cross-reactivity of human antibodies to a 33-mer peptide of the alpha-gliadin component of gluten with Bordetella pertussis pertactin

He Q; Viljanen MK; Hinkkanen AE; Arvilommi H; Mertsola J; Viander M
Vaccine (2005)

Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy

Lehtinen M; Idänpää-Heikkilä I; Lunnas T; Palmroth J; Barr E; Cacciatore R; Isaksson R; Kekki M; Koskela P; Kosunen E; Kuortti M; Lahti L; Liljamo T; Luostarinen T; Apter D; Pukkala E; Paavonen J
INT J STD AIDS : 4 (2006)

Rokkotteiden haittavaikutukset ja niiden ilmoittaminen

Heinäsmäki T; Kilpi T; Lankinen KS
Suom Lääkäril : 20-21 (1998)

Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s

Lehtinen M; Kaasila M; Pasanen K; Patama T; Palmroth; Laukkanen P; Pukkala E; Koskela P
Int J Cancer (2006)

Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland

French KM; Barnabas RV; Lehtinen M; Kontula O; Pukkala E; Dillner J; Garnett GP
Br J Cancer : 3 (2007)

Strengthening prevention programs to eliminate cervical cancer in the Nordic countries

Dillner L; Pagliusi S; Bray F; Lorincz A; Kjaer SK; Anttila A; Iversen OE; Dillner J; Lehtinen M; Paavonen J
Acta Obstet Gynecol Scand : 5 (2008)

Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries (Chapter 28)

Lehtinen M; Herrero R; Mayaud P; Barnabas R; Dillner J; Paavonen J; Smith PG
Vaccine : S3 (2006)

"VACCINATION" - Selaus asiasanan mukaan Kansanterveyslaitos KTL

Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study ﻿

Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV 16 vaccination ﻿

Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise ﻿

Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing ﻿

Low mumps antibody levels induced by mumps-measles-rubella vaccinations in type 1 diabetic children ﻿

No evidence of cross-reactivity of human antibodies to a 33-mer peptide of the alpha-gliadin component of gluten with Bordetella pertussis pertactin ﻿

Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy ﻿

Rokkotteiden haittavaikutukset ja niiden ilmoittaminen ﻿

Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s ﻿

Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland ﻿

Strengthening prevention programs to eliminate cervical cancer in the Nordic countries ﻿

Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries (Chapter 28) ﻿